Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
40 hedge funds and large institutions have $8.8M invested in Soleno Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 8 closing their positions.
380% more call options, than puts
Call options by funds: $24K | Put options by funds: $5K
1.52% less ownership
Funds ownership: 4.23% → 2.71% (-1.5%)
2% less funds holding
Funds holding: 41 → 40 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
27% less capital invested
Capital invested by funds: $12M → $8.8M (-$3.21M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$27.8K |
| 3 |
VF
Virtu Financial
New York
|
+$12.5K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$11.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$313K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$81K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$56K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$29K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$24.7K |
SLNO Hedge Fund Activity: Q2 2022 in Review
40 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2022, worth a combined $8.8M — down 27% from $12M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SLNO and 7 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $55.7K. The largest seller was Empery Asset Management, exiting entirely with an estimated $313K sold.
- 40 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $8.8M of Soleno Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
- 7 funds opened new Soleno Therapeutics positions in Q2 2022 and 8 closed out, a net change of -1 holder.
- The largest Soleno Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $55.7K added.
- The largest Soleno Therapeutics seller in Q2 2022 was Empery Asset Management, an estimated $313K sold.
Based on aggregated 13F filings for Q2 2022.